Skip to main content
. 2016 Apr 30;214(3):408–416. doi: 10.1093/infdis/jiw173

Table 1.

Baseline Characteristics Participants in the Control Arms of SMART and ESPRIT

Characteristic Overall (n = 4304) All-Cause Death (n = 157) Non–AIDS-Related, Nonviolent, Unintentional Death (n = 117) AIDS (n = 101) CVD (n = 121) Non–AIDS-Defining Malignancy (n = 99)
Age, y 42 [36, 49] 48 [40, 54] 48 [41, 55] 44 [38, 50] 49 [43, 56] 50 [44, 57]
Female sex 1002 (23.3) 28 (17.8) 17 (14.5) 22 (21.8) 14 (11.6) 14 (14.1)
Black race 907 (21.1) 29 (18.5) 25 (21.4) 18 (17.8) 26 (21.5) 26 (26.3)
BMIa 24.4 [22.1, 27.1] 23.5 [21.4, 27.3] 23.3 [21.3, 27.1] 25.2 [22.6, 29.0] 24.0 [22.1, 27.4] 23.9 [21.7, 25.8]
Prior AIDS 1093 (25.4) 46 (29.3) 32 (27.4) 42 (41.6) 47 (38.8) 21 (21.2)
Hepatitis B/C 761 (17.7) 54 (34.4) 41 (35.0) 16 (15.8) 18 (14.9) 27 (27.3)
Prior CVD 112 (2.6) 14 (9.0) 12 (10.3) 1 (1.0) 16 (13.3) 5 (5.1)
Diabetes 217 (5.1) 14 (9.0) 10 (8.6) 7 (6.9) 14 (11.7) 9 (9.1)
PI-based ART 1478 (34.3) 53 (33.8) 45 (38.5) 31 (30.7) 52 (43.0) 41 (41.4)
NNRTI-based ART 1643 (38.2) 52 (33.1) 39 (33.3) 34 (33.7) 30 (24.8) 30 (30.3)
CD4+ T-cell count, cells/mm3
Baseline 526 [415, 701] 451 [370, 594] 470 [384, 639] 466 [376, 599] 515 [401, 673] 526 [404, 679]
Nadir 230 [120, 337] 194 [93, 297] 194 [85, 282] 190 [90, 298] 187 [74, 301] 219 [97, 311]
HIV RNA load ≤500 copies/mL 3263 (75.8) 97 (61.8) 77 (65.8) 51 (50.5) 88 (72.7) 75 (75.8)
IL-6, pg/mL 1.80 [1.18, 2.90] 3.09 [2.10, 4.40] 3.17 [2.10, 4.49] 2.42 [1.40, 3.33] 2.60 [1.78, 4.30] 2.50 [1.81, 3.58]
hsCRP, µg/mL 1.60 [0.69, 3.67] 2.83 [1.53, 6.27] 2.70 [1.57, 6.18] 2.03 [0.83, 4.50] 2.33 [1.02, 5.05] 2.54 [1.13, 4.93]
D-dimer, µg/mL 0.24 [0.15, 0.38] 0.33 [0.23, 0.55] 0.35 [0.23, 0.55] 0.31 [0.22, 0.53] 0.31 [0.20, 0.51] 0.28 [0.18, 0.52]

Data are no. (%) of subjects or median value (interquartile range).

Abbreviations: ART, antiretroviral therapy; CVD, cardiovascular disease; HIV, human immunodeficiency virus; hsCRP, high-sensitivity C-reactive protein; IL-6, interleukin 6; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI, protease inhibitor.

a Body mass index (BMI) is calculated as the weight in kilograms divided by the height in meters squared.